Cross Cancer Institute ( Site 0111)

Edmonton, Alberta T6G 1Z2

0 studies enrolling now · 1 studies all time

What they study most

Carcinoma, Renal Cell

Studies at this site

• A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) — Running, not enrolling